Cardiometabolic & GLP-1

Understand why people start, stop, and switch GLP-1 therapies

See how cost, side effects, behavior, and treatment experience shape real-world GLP-1 use, beyond what is visible in claims data.

talk to an expertexplore the data
AT A GLANCE
165K
people in our GLP-1 market insights
60K+
individuals in our GLP-1 dosing analysis
24%
of 119K people trying to lose weight have used a weight-loss Rx
~500
adults with BMI ≥25 recruited in three weeks

GLP-1 adherence and discontinuation are not well understood

Teams can track prescriptions and persistence, but not why people pause, switch, or stop.

The gap

What today's data miss

  • Why patients discontinue after initiation
  • How side effects, cost, and daily experience affect adherence
  • What drives switching between therapies or doses
  • Why eligible patients never start

Open questions

What life sciences teams are asking

  • What are the most common reasons for drop-off?
  • How do side effects affect persistence?
  • What influences switching between GLP-1 treatments?
  • How does real-world behavior differ from trial assumptions?

Our approach

A different way to see GLP-1 behavior

  • Longitudinal tracking within the same people
  • Real-time insight into adherence and decisions
  • Recontact at initiation, switching, or drop-off
  • Treatment experience beyond clinical settings

Data to understand what drives GLP-1 treatment

What people experience, decide, and do over time, not just what is recorded in claims or clinical visits.

Who patients are
  • Age, sex, gender identity, race and ethnicity
  • Income, education, employment, household
  • Insurance, out-of-pocket costs, affordability
  • Access barriers: transportation, food, care
What they want
  • Weight goals and satisfaction with progress
  • Motivations: health, appearance, energy
  • Beliefs about what drives weight
What they do
  • Diet, activity, sleep, stress, substance use
  • Apps, programs, and support communities
  • Medication history across GLP-1 and alternatives
Why some never start
  • Cost and insurance barriers
  • Side effect concerns and injection aversion
  • Low perceived need or preference for other approaches
Treatment decisions
  • Injectable vs. oral, branded vs. compounded
  • Titration and microdosing behaviors
  • HCP, telehealth, and direct-to-consumer access
Preferences
  • Flexible dosing vs. convenience
  • Simplicity vs. control
  • Drivers of microdosing: side effects and cost
Why people drop off
  • Cost and affordability over time
  • Side effect type, severity, and persistence
  • Burden, complexity, and adherence friction
Real-world outcomes
  • Weight trajectory and total loss
  • Physical and functional changes
  • Satisfaction, goals, and quality of life
talk to us about GLP-1 insights
Trusted by leading life sciences companies:

Real-world insights on GLP-1 and cardiometabolic health

Insights into GLP-1 adherence, discontinuation, and treatment behavior from the Evidation Community.

GLP-1 Use Is Growing, but Adoption Is Uneven
New insights from Evidation explore who remains outside GLP-1 treatment and how cost, coverage, information, and real-world experience may shape access.
Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market
Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.
ISPOR 2026 Recap: Understanding Health Between Visits
Evidation’s research at ISPOR 2026 highlighted the growing need for direct, longitudinal patient data to better understand real-world outcomes
‍Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
New insights from Evidation’s cardiometabolic health and weight management cohort, comprised of over 160,000 individuals, show what factors shape real-world dosing decisions.
A New Model for Real-World Data in Weight and Metabolic Health
Evidation’s BODEE-Weight Study recruited nearly 500 adults with BMI ≥25 in three weeks, pairing self-report, wearables, and EHR data to deliver a new interactive model for real-world evidence.
Measuring Real-World Cardiometabolic Health Using Wearable-Derived Data
Evidation's cardiometabolic score, developed through wearable derived data, can reveal subtle shifts in health that precede clinical diagnosis, offering a scalable, privacy-centric way to assess risk, monitor change, and engage individuals.
<  Previous
|
Next  >

Let's design your next study

Tell us the question you need to answer. Our scientists will show you which cohorts, data types, and study designs can get you there, and how quickly.

talk to an expertsubscribe to our newsletter